Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
Open accessAbstract
With the use of a mouse model expressing human Fc-gamma receptors (FcγRs), we demonstrated that antibodies with isotypes equivalent to ipilimumab and tremelimumab mediate intra-tumoral regulatory T (Treg) cell depletion in vivo , increasing the CD8 + to Treg cell ratio and promoting tumor rejection. Antibodies with improved FcγR binding profiles drove superior anti-tumor responses and survival. In patients with advanced melanoma, response to ipilimumab was associated with the CD16a-V158F high affinity polymorphism. Such activity only appeared relevant in the context of inflamed tumors, explaining the modest response rates observed in the clinical setting. Our data suggest that the activity of anti-CTLA-4 in inflamed tumors may be improved through enhancement of FcγR binding, whereas poorly infiltrated tumors will likely require combination approaches.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Multiple studies have confirmed that antibody-dependent cell-mediated cytotoxicity of Treg also substantially contributes to the antitumor activity of ipilimumab.
“However, multiple studies have been confirmed that antibody-dependent cell-mediated cytotoxicity of Treg also substantially contributes to the antitumor activity of ipilimumab [128–130].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [130]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,314 · see citing works
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · see citing works
Self-citationSignatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · see citing works
Self-citationCombined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157 · see citing works
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519 · see citing works
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496 · see citing works
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286 · see citing works
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230 · cited 3× · see citing works
“Modulation of co-inhibitory and co-stimulatory immune checkpoint molecules on tumor-reactive lymphocytes has emerged as a promising therapeutic strategy for a variety of cancers (Hodi et al., 2010; Larkin et al., 2015; Ribas et al., 2015; Robert et al., 2011, 2014, 2015; Weber et al., 2015; Wolchok et al., 2013).”
BackgroundEnhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955 · see citing works
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448 · see citing works
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065 · see citing works
Self-citationCTLA-4 Control over Foxp3 <sup>+</sup> Regulatory T Cell Function
Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956 · see citing works
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., et al. (2015) · Science · doi:10.1126/science.aad0095 · Cited by 2,839 · see citing works
Weber, J. S., D’Angelo, S. P., Minor, D. R., Hodi, F. S., Gutzmer, R., Neyns, B., Höeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,676 · see citing works
Self-citationRead, S., Malmström, V., & Powrie, F. M. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,206 · see citing works
Schadendorf, D., Hodi, F. S., Robert, C., Weber, J. S., Margolin, K., Hamid, O., Patt, D., Chen, T.-T., Berman, D. M., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2736 · Cited by 2,141 · see citing works
Cartron, G., Dacheux, L., Salles, G., Solal‐Céligny, P., BARDOS, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,902 · see citing works
Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835 · see citing works
Robert, C., Ribas, A., Wolchok, J. D., Hodi, F. S., Hamid, O., Kefford, R., Weber, J. S., Joshua, A. M., Hwu, W.-J., Gangadhar, T. C., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60958-2 · Cited by 1,774 · see citing works
Ribas, A., Puzanov, I. J., Dummer, R., Schadendorf, D., Hamid, O., Robert, C., Hodi, F. S., Schachter, J., Pavlick, A. C., Lewis, K. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00083-2 · Cited by 1,580 · see citing works
Bruhns, P., Iannascoli, B., England, P., Mancardi, D. A., Fernandez, N., Jorieux, S., & Daëron, M. (2009) · Blood · doi:10.1182/blood-2008-09-179754 · Cited by 1,479 · see citing works
Simpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130579 · Cited by 1,472 · see citing works
Self-citationWeng, W., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,300 · see citing works
Shields, R. L., Namenuk, A. K., Hong, K., Meng, Y. G., Rae, J., Briggs, J. B., Xie, D., Lai, J., Stadlen, A., Li, B., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009483200 · Cited by 1,164 · see citing works
Musolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8957 · Cited by 981 · see citing works
Peggs, K. S., Quezada, S. A., Chambers, C. A., Korman, A. J., & Allison, J. P. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082492 · Cited by 967 · see citing works
Turajlic, S., Litchfield, K., Xu, H., Rosenthal, R., McGranahan, N., Reading, J. L., Wong, Y. N. S., Rowan, A., Kanu, N., Bakir, M. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30516-8 · Cited by 909 · see citing works
Self-citationSelby, M. J., Engelhardt, J. J., Quigley, M., Henning, K. A., Chen, T., Srinivasan, M., & Korman, A. J. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0013 · Cited by 857 · see citing works
Engineered antibody Fc variants with enhanced effector function
Lazar, G. A., Dang, W., Karki, S., Vafa, O., Peng, J. S., Hyun, L., Chan, C. S. C., Chung, H. S., Eivazi, A., Yoder, S. C., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508123103 · Cited by 805 · see citing works
Koene, H. R., Kleijer, M., Algra, J., Roos, D., Borne, A. E. G. K. V. D., & de Haas, M. (1997) · Blood · doi:10.1182/blood.v90.3.1109 · Cited by 796 · see citing works
Wu, J., Edberg, J. C., Redecha, P. B., Bansal, V., Guyre, P. M., Coleman, K. D., Salmon, J. E., & Kimberly, R. P. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119616 · Cited by 711 · see citing works
Quezada, S. A. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27745 · Cited by 700 · cited 2× · see citing works
“…that, in the context of human FcgRhuman IgG interactions in vivo, depletion of tumor-infiltrating Treg cells is a major contributor to the shift in this ratio, which has previously been associated with therapeutic responses in mouse and humans (Hodi et al., 2008; Quezada et al., 2006).”
BackgroundRegulatory T Cells Exhibit Distinct Features in Human Breast Cancer
Plitas, G., Konopacki, C., Wu, K., Bos, P. D., Morrow, M., Putintseva, E. V., Chudakov, D. M., & Rudensky, A. Y. (2016) · Immunity · doi:10.1016/j.immuni.2016.10.032 · Cited by 695 · see citing works
De Simone, M., Arrigoni, A., Rossetti, G., Gruarin, P., Ranzani, V., Politano, C., Bonnal, R. J. P., Provasi, E., Sarnicola, M. L., Panzeri, I., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.10.021 · Cited by 687 · see citing works
Hodi, F. S., Butler, M., Oble, D. A., Seiden, M. V., Haluska, F. G., Kruse, A., MacRae, S., Nelson, M., Canning, C., Lowy, I., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712237105 · Cited by 650 · see citing works
Romano, E., Kusio-Kobialka, M., Foukas, P. G., Baumgaertner, P., Meyer, C., Ballabeni, P., Michielin, O., Weide, B., Romero, P., & Speiser, D. E. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1417320112 · Cited by 601 · see citing works
Zhang, W., Gordon, M. A., Schultheis, A. M., Yang, D., Nagashima, F., Azuma, M., Chang, H.-M., Borucka, E., Lurje, G., Sherrod, A. E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.8021 · Cited by 482 · see citing works
Warmerdam, P. A. M., van de Winkel, J. G. J., Vlug, A., WESTERDAAL, N. A. C., & Capel, P. J. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.4.1338 · Cited by 463 · see citing works
Bulliard, Y., Jolicoeur, R., Windman, M., Rue, S. M., Ettenberg, S. A., Knee, D. A., Wilson, N. S., Dranoff, G., & Brogdon, J. L. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20130573 · Cited by 446 · see citing works
Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo
Read, S., Greenwald, R., Izcue, A., Robinson, N., Mandelbrot, D., Francisco, L., Sharpe, A. H., & Powrie, F. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.7.4376 · Cited by 434 · see citing works
Parren, P. W. H. I., Warmerdam, P. A. M., Boeije, L. C. M., Arts, J. A. J., WESTERDAAL, N. A. C., Vlug, A., Capel, P. J., Aarden, L. A., & van de Winkel, J. G. J. (1992) · Journal of Clinical Investigation · doi:10.1172/jci116022 · Cited by 346 · see citing works
Tarhini, A. A., Edington, H. D. J., Butterfield, L. H., Lin, Y., Shuai, Y., Tawbi, H. A., Sander, C., Yin, Y., Holtzman, M. P., Johnson, J. T., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087705 · Cited by 310 · see citing works
Mouse model recapitulating human Fcγ receptor structural and functional diversity
Smith, P. T., DiLillo, D. J., Bournazos, S., Li, F., & Ravetch, J. V. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203954109 · Cited by 298 · see citing works
Localization of the binding site for the human high-affinity Fc receptor on IgG
Duncan, A., Woof, J. M., Partridge, L. J., Burton, D. R., & Winter, G. P. (1988) · Nature · doi:10.1038/332563a0 · Cited by 288 · see citing works
OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy
Bulliard, Y., Jolicoeur, R., Zhang, J., Dranoff, G., Wilson, N. S., & Brogdon, J. L. (2014) · Immunology and Cell Biology · doi:10.1038/icb.2014.26 · Cited by 285 · see citing works
Salmon, J. E., Edberg, J. C., Brogle, N. L., & Kimberly, R. P. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115712 · Cited by 280 · see citing works
Jie, H.-B., Schuler, P. J., Lee, S. C., Srivastava, R. M., Argiris, A. E., Ferrone, S., Whiteside, T. L., & Ferris, R. L. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2788 · Cited by 267 · see citing works
Schneider‐Merck, T., van Bueren, J. J. L., Berger, S., Rossen, K., van Berkel, P. H. C., Derer, S., Beyer, T. D., Lohse, S., Bleeker, W. K., Peipp, M., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900847 · Cited by 223 · see citing works
Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade
Nathanson, T., Ahuja, A., Rubinsteyn, A., Aksoy, B. A., Hellmann, M. D., Miao, D., Allen, E. M. V., Merghoub, T., Wolchok, J. D., Snyder, A., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0019 · Cited by 208 · see citing works
Sanders, E. A. M., Feldman, R. G., Voorhorst‐Ogink, M. M., de Haas, M., Rijkers, G. T., Capel, P. J., ZEGERS, B. J. M., & van de Winkel, J. G. J. (1995) · Infection and Immunity · doi:10.1128/iai.63.1.73-81.1995 · Cited by 197 · see citing works
Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy
Coe, D., Begom, S., Addey, C., White, M., Dyson, J., & Chai, J. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0866-5 · Cited by 168 · see citing works
Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies
Furness, A. J. S., Vargas, F. A., Peggs, K. S., & Quezada, S. A. (2014) · Trends in Immunology · doi:10.1016/j.it.2014.05.002 · Cited by 119 · see citing works
Self-citationSármay, G., Lund, J., Rozsnyay, Z., Gergely, J., & Jefferis, R. (1992) · Molecular Immunology · doi:10.1016/0161-5890(92)90200-h · Cited by 109 · see citing works
Tremelimumab: research and clinical development
Ibarrondo, F. J., Comin-Anduix, B., & Escuin-Ordinas, H. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s65802 · Cited by 84 · see citing works
The influence of the hinge region length in binding of human IgG to human Fcγ receptors
Redpath, S., Michaelsen, T. E., Sandlie, I., & Clark, M. (1998) · Human Immunology · doi:10.1016/s0198-8859(98)00075-5 · Cited by 45 · see citing works
Preclinical in vitro characterization of anti-CTLA4 therapeutic antibody CP-675,206.
Hanson, D. C., Canniff, P. C., Primiano, M. J., Donovan, C. B., Gardner, J. P., Natoli, E. J., Morgan, R. W., Mather, R. J., Singleton, D. H., Hermes, P., et al. (2004) · Cancer Research · Cited by 37 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445 · see citing works
Human FOXP3+ Regulatory T Cell Heterogeneity and Function in Autoimmunity and Cancer
Wing, J. B., Tanaka, A., & Sakaguchi, S. (2019) · Immunity · doi:10.1016/j.immuni.2019.01.020 · Cited by 726 · see citing works
Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
Yi, M., Jiao, D., Qin, S., Chu, Q., Wu, K., & Li, A. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0974-6 · Cited by 608 · see citing works
The hallmarks of successful anticancer immunotherapy
Galluzzi, L., Chan, T. A., Kroemer, G., Wolchok, J. D., & López-Soto, A. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat7807 · Cited by 575 · see citing works
Benci, J. L., Johnson, L. R., Choa, R., Xu, Y., Qiu, J., Zhou, Z., Xu, B., Ye, D., Nathanson, K. L., June, C. H., et al. (2019) · Cell · doi:10.1016/j.cell.2019.07.019 · Cited by 541 · see citing works
Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy
Li, A., Yi, M., Qin, S., Song, Y., Chu, Q., & Wu, K. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0721-x · Cited by 413 · see citing works
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers
Sharma, A., Subudhi, S. K., Blando, J., Scutti, J., Vence, L., Wargo, J., Allison, J. P., Ribas, A., & Sharma, P. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0762 · Cited by 382 · see citing works
Wei, S. C., Anang, N.-A. A. S., Sharma, R., Andrews, M. C., Reuben, A., Levine, J. H., Cogdill, A. P., Mancuso, J. J., Wargo, J. A., Pe’er, D., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1821218116 · Cited by 359 · see citing works
p53, cancer and the immune response
Blagih, J., Buck, M. D., & Vousden, K. H. (2020) · Journal of Cell Science · doi:10.1242/jcs.237453 · Cited by 333 · see citing works
Śledzińska, A., Vila de Mucha, M., Bergerhoff, K., Hotblack, A., Demane, D. F., Ghorani, E., Akarca, A. U., Marzolini, M. A. V., Solomon, I., Vargas, F. A., et al. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.007 · Cited by 228 · see citing works
Self-citationHa, D., Tanaka, A., Kibayashi, T., Tanemura, A., Sugiyama, D., Wing, J. B., Lim, E. L., Teng, K. W. W., Adeegbe, D., Newell, E. W., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1812186116 · Cited by 205 · see citing works
Dovedi, S. J., Elder, M. J., Yang, C., Sitnikova, S. I., Irving, L., Hansen, A., Hair, J., Jones, D. C., Hasani, S., Wang, B., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1445 · Cited by 186 · see citing works
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors
Skoulidis, F., Araujo, H. A., Do, M. T., Qian, Y., Sun, X., Galan-Cobo, A., Le, J. T., Montesion, M., Palmer, R., Jahchan, N., et al. (2024) · Nature · doi:10.1038/s41586-024-07943-7 · Cited by 194 · see citing works
Self-citationde Charette, M., & Houot, R. (2018) · Haematologica · doi:10.3324/haematol.2017.184192 · Cited by 129 · see citing works
Plitas, G., & Rudensky, A. Y. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033428 · Cited by 148 · see citing works
Mechanisms of immune checkpoint inhibitor-mediated liver injury
Shojaie, L., Ali, M., Iorga, A., & Dara, L. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.10.003 · Cited by 98 · see citing works
Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells
Tanaka, A., Nishikawa, H., Noguchi, S., Sugiyama, D., Morikawa, H., Takeuchi, Y., Ha, D., Shigeta, N., Kitawaki, T., Maeda, Y., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20191009 · Cited by 96 · see citing works
Beavis, P. A., Henderson, M. A., Giuffrida, L., Davenport, A. J., Petley, E. V., House, I. G., Lai, J., Sek, K., Milenkovski, N., John, L. B., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0291 · Cited by 68 · see citing works
Berezhnoy, A., Sumrow, B. J., Stahl, K., Shah, K., Liu, D., Li, J., Hao, S.-S., De Costa, A., Kaul, S., Bendell, J., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100163 · Cited by 56 · see citing works
Learning from the nexus of autoimmunity and cancer
Mangani, D., Yang, D., & Anderson, A. C. (2023) · Immunity · doi:10.1016/j.immuni.2023.01.022 · Cited by 33 · see citing works
Impact of Immunotherapy on CD4 T Cell Phenotypes and Function in Cancer
Saillard, M., Cenerenti, M., Romero, P., & Jandus, C. (2021) · Vaccines · doi:10.3390/vaccines9050454 · Cited by 23 · see citing works
How does the gut microbiome influence immune checkpoint blockade therapy?
Almonte, A. A., Rangarajan, H., Yip, D., & Fahrer, A. M. (2021) · Immunology & Cell Biology · doi:10.1111/imcb.12423 · Cited by 21 · see citing works
- Authors
- Arce Vargas, F., Furness, A. J. S., Litchfield, K., Joshi, K., Rosenthal, R., Ghorani, E., Solomon, I., Lesko, M. H., Ruef, N., Roddie, C., Henry, J. Y., Spain, L., Ben Aissa, A., Georgiou, A., Wong, Y. N. S., Smith, M., Strauss, D., Hayes, A., Nicol, D., O'Brien, T., Mårtensson, L., Ljungars, A., Teige, I., Frendéus, B., Harrington, K., Melcher, A., Wotherspoon, A., Francis, N., Challacombe, B., Fernando, A., Hazell, S., Chandra, A., Pickering, L., Lynch, J., Rudman, S., Chowdhury, S., Harrison-Phipps, K., Varia, M., Horsfield, C., Polson, A., Stamp, G., O'Donnell, M., Drake, W., Hill, P., Hrouda, D., Mayer, E., Olsburgh, J., Kooiman, G., O'Connor, K., Stewart, G., Aitchison, M., Tran, M., Fotiadis, N., Verma, H., Lopez, J., Lester, J., Morgan, F., Kornaszewska, M., Attanoos, R., Adams, H., Davies, H., Fennell, D., Shaw, J., Le Quesne, J., Nakas, A., Rathinam, S., Monteiro, W., Marshall, H., Nelson, L., Bennett, J., Riley, J., Primrose, L., Martinson, L., Anand, G., Khan, S., Nicolson, M., Kerr, K., Palmer, S., Remmen, H., Miller, J., Buchan, K., Chetty, M., Gomersall, L., Lock, S., Naidu, B., Langman, G., Trotter, S., Bellamy, M., Bancroft, H., Kerr, A., Kadiri, S., Webb, J., Middleton, G., Djearaman, M., Summers, Y., Califano, R., Taylor, P., Shah, R., Krysiak, P., Rammohan, K., Fontaine, E., Booton, R., Evison, M., Crosbie, P., Moss, S., Idries, F., Novasio, J., Joseph, L., Bishop, P., Chaturvedi, A., Marie Quinn, A., Doran, H., leek, A., Harrison, P., Moore, K., Waddington, R., Blackhall, F., Rogan, J., Smith, E., Dive, C., Brady, G., Rothwell, D., Gulati, S., Chemie, F., Tugwood, J., Pierce, J., Lawrence, D., Hayward, M., Panagiotopoulos, N., George, R., Patrini, D., Falzon, M., Borg, E., Khiroya, R., Jamal-Hanjani, M., Wilson, G., Juul Birkbak, N., Watkins, T., McGranahan, N., Abbosh, C., Horswell, S., Mitter, R., Escudero, M., Stewart, A., Rowan, A., Hiley, C., Goldman, J., Ahmed, A., Taylor, M., Choudhary, J., Shaw, P., Veeriah, R., Czyzewska-Khan, J., Johnson, D., Laycock, J., Hynds, R., Werner Sunderland, M., Reading, J., Novelli, M., Oukrif, D., Janes, S., Forster, M., Ahmad, T., Ming Lee, S., van Loo, P., Herrero, J., Hartley, J., Kevin Stone, R., Denner, T., Costa, M., Begum, S., Phillimore, B., Chambers, T., Nye, E., Ward, S., Elgar, G., Al-Bakir, M., Carnell, D., Mendes, R., George, J., Navani, N., Papadatos-Pastos, D., Scarci, M., Gorman, P., Lowe, H., Ensell, L., Moore, D., MacKenzie, M., Wilcox, M., Bell, H., Hackshaw, A., Ngai, Y., Smith, S., Gower, N., Ottensmeier, C., Chee, S., Johnson, B., Alzetani, A., Shaw, E., Lim, E., De Sousa, P., Tavares Barbosa, M., Nicholson, A., Bowman, A., Jordan, S., Rice, A., Raubenheimer, H., Proli, C., Elena Cufari, M., Carlo Ronquillo, J., Kwayie, A., Bhayani, H., Hamilton, M., Bakar, Y., Mensah, N., Ambrose, L., Devaraj, A., Buderi, S., Finch, J., Azcarate, L., Chavan, H., Green, S., Mashinga, H., Lau, K., Sheaff, M., Schmid, P., Conibear, J., Ezhil, V., Prakash, V., Danson, S., Bury, J., Edwards, J., Hill, J., Matthews, S., Kitsanta, Y., Suvarna, K., Shackcloth, M., Gosney, J., Postmus, P., Feeney, S., Asante-Siaw, J., Russell, P., Light, T., Horey, T., Blyth, K., Dick, C., Kirk, A., Pule, M., Marafioti, T., Gore, M., Larkin, J., Turajlic, S., Swanton, C., Peggs, K. S., & Quezada, S. A.
- Affiliations
- Royal Marsden NHS Foundation Trust (GB)
- The Francis Crick Institute (GB)
- Cancer Research UK (GB)
- University College London (GB)
- Guy's Hospital (GB)
- BioInvent (Sweden) (SE)
- University College Hospital (GB)
- Corresponding author
- Peggs, Karl S.
- Quezada, Sergio A.
- ORCID
- Furness, Andrew J.S.
- Litchfield, Kevin
- Rosenthal, Rachel
- Ghorani, Ehsan
- Solomon, Isabelle
- Ruef, Nora
- Roddie, Claire
- Henry, Jake Y.
- Spain, Lavinia
- Georgiou, Andrew
- Wong, Yien Ning Sophia
- Smith, Myles
- Strauss, Dirk
- Hayes, Andrew
- Nicol, David
- Mårtensson, Linda
- Ljungars, Anne
- Teige, Ingrid
- Frendéus, Björn
- Harrington, Kevin
- Melcher, Alan
- Wotherspoon, Andrew
- Challacombe, Ben
- Hazell, Steve
- Pickering, Lisa
- Lynch, Joanna
- Rudman, Sarah
- Horsfield, Catherine
- Polson, Alexander
- Hrouda, David
- Stewart, Grant
- Aitchison, Michael
- Tran, Maxine
- Fotiadis, Nicos
- Lopez, Jose
- Lester, Jason
- Fennell, Dean
- Shaw, Jacqui
- Nakas, Apostolos
- Rathinam, Sridhar
- Primrose, Lindsay
- Khan, Sajid
- Naidu, Babu
- Webb, Joanne
- Middleton, Gary
- Djearaman, Madava
- Summers, Yvonne
- Califano, Raffaele
- Shah, Rajesh
- Krysiak, Piotr
- Booton, Richard
- Evison, Matthew
- Moss, Stuart
- Chaturvedi, Anshuman
- Blackhall, Fiona
- Dive, Caroline
- Rothwell, Dominic
- Gulati, Sakshi
- Lawrence, David
- Panagiotopoulos, Nikolaos
- Patrini, Davide
- Falzon, Mary
- Borg, Elaine
- Wilson, Gareth
- Watkins, Thomas
- McGranahan, Nicholas
- Abbosh, Christopher
- Horswell, Stuart
- Mitter, Richard
- Escudero, Mickael
- Rowan, Andrew
- Hiley, Crispin
- Goldman, Jacki
- Johnson, Diana
- Laycock, Joanne
- Hynds, Robert
- Reading, James
- Novelli, Marco
- Oukrif, Dahmane
- Janes, Sam
- Forster, Martin
- Herrero, Javier
- Hartley, John
- Costa, Marta
- Begum, Sharmin
- Nye, Emma
- Elgar, Greg
- Carnell, Dawn
- Mendes, Ruheena
- Navani, Neal
- Scarci, Marco
- Lowe, Helen
- Ensell, Leah
- Moore, David
- Wilcox, Maggie
- Hackshaw, Allan
- Smith, Sean
- Ottensmeier, Christian
- Chee, Serena
- Alzetani, Aiman
- Shaw, Emily
- Lim, Eric
- Nicholson, Andrew
- Rice, Alexandra
- Sheaff, Michael
- Conibear, John
- Prakash, Vineet
- Danson, Sarah
- Edwards, John
- Hill, Jennifer
- Shackcloth, Michael
- Gosney, John
- Postmus, Pieter
- Kirk, Alan
- Marafioti, Teresa
- Larkin, James
- Turajlic, Samra
- Swanton, Charles
- Peggs, Karl S.
- Quezada, Sergio A.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2018-04
- Volume
- 33
- Issue
- 4
- Pages
- 649-663.e4
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC5904288
- OpenAlex
- W2792557198
- Cited by
- 592
- References
- 57
- Citations by year
- 2026: 44 · 2025: 57 · 2024: 58 · 2023: 70 · 2022: 79 · 2021: 87 · 2020: 81 · 2019: 76 · 2018: 39
- FWCI
- 26.59
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Cancer Cell (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- Apollo (University of Cambridge) (submittedVersion, cc-by)
- UCL Discovery (University College London) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Leicester Research Archive (University of Leicester) (submittedVersion, cc-by)
- Research Explorer (The University of Manchester) (submittedVersion, other-oa)
- Apollo (cc-by)
- Funders
- Cancer Research UK (C36463 / A22246, C11496 / A17786, C33499 / A20265)
- Manchester Biomedical Research Centre
- National Institute for Health Research
- UCLH Biomedical Research Centre
- Department of Health and Social Care
- Institute of Cancer Research (C36463 / A20764)
- Rockefeller University
- University College London
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- anti-CTLA-4 antibody, Fc effector functions, Fc gamma receptor, ipilimumab, tremelimumab, Treg depletion, melanoma, tumor inflammation, tumor rejection, CD8+ T cells
- MeSH terms
- Antineoplastic Agents, Immunological, Ipilimumab, Animals, Antibodies, Monoclonal, Female, Humans, Melanoma, Treatment Outcome, Receptors, IgG, Polymorphism, Single Nucleotide, Xenograft Model Antitumor Assays, Cell Line, Tumor, T-Lymphocytes, Regulatory, Mice, CTLA-4 Antigen, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
